» Articles » PMID: 35009984

Lateral Flow Immunoassay with Quantum-Dot-Embedded Silica Nanoparticles for Prostate-Specific Antigen Detection

Abstract

Prostate cancer can be detected early by testing the presence of prostate-specific antigen (PSA) in the blood. Lateral flow immunoassay (LFIA) has been used because it is cost effective and easy to use and also has a rapid sample-to-answer process. Quantum dots (QDs) with very bright fluorescence have been previously used to improve the detection sensitivity of LFIAs. In the current study, a highly sensitive LFIA kit was devised using QD-embedded silica nanoparticles. In the present study, only a smartphone and a computer software program, ImageJ, were used, because the developed system had high sensitivity by using very bright nanoprobes. The limit of PSA detection of the developed LFIA system was 0.138 ng/mL. The area under the curve of this system was calculated as 0.852. The system did not show any false-negative result when 47 human serum samples were analyzed; it only detected PSA and did not detect alpha-fetoprotein and newborn calf serum in the samples. Additionally, fluorescence was maintained on the strip for 10 d after the test. With its high sensitivity and convenience, the devised LFIA kit can be used for the diagnosis of prostate cancer.

Citing Articles

Aptamer-Conjugated Multi-Quantum Dot-Embedded Silica Nanoparticles for Lateral Flow Immunoassay.

Yoo K, Cho H, Kim J, Shin M, Chu J, Jang S Biosensors (Basel). 2025; 15(1).

PMID: 39852105 PMC: 11763673. DOI: 10.3390/bios15010054.


Synthesis and Application of Optical Nanomaterials.

Jun B Nanomaterials (Basel). 2024; 14(23).

PMID: 39683293 PMC: 11643386. DOI: 10.3390/nano14231904.


Highly sensitive multiplexed colorimetric lateral flow immunoassay by plasmon-controlled metal-silica isoform nanocomposites: PINs.

Shin M, Kim W, Yoo K, Cho H, Jang S, Bae H Nano Converg. 2024; 11(1):42.

PMID: 39446245 PMC: 11502615. DOI: 10.1186/s40580-024-00449-y.


Lateral flow assays: Progress and evolution of recent trends in point-of-care applications.

Kakkar S, Gupta P, Singh Yadav S, Raj D, Singh G, Chauhan S Mater Today Bio. 2024; 28:101188.

PMID: 39221210 PMC: 11364909. DOI: 10.1016/j.mtbio.2024.101188.


Classification and applications of nanomaterials diagnosis.

Lai H, Huang R, Weng X, Huang B, Yao J, Pian Y Heliyon. 2024; 10(11):e32314.

PMID: 38868029 PMC: 11168482. DOI: 10.1016/j.heliyon.2024.e32314.


References
1.
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J . Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2007; 19(2):175-81. PMC: 3064270. DOI: 10.1007/s10552-007-9083-8. View

2.
Rong Z, Bai Z, Li J, Tang H, Shen T, Wang Q . Dual-color magnetic-quantum dot nanobeads as versatile fluorescent probes in test strip for simultaneous point-of-care detection of free and complexed prostate-specific antigen. Biosens Bioelectron. 2019; 145:111719. DOI: 10.1016/j.bios.2019.111719. View

3.
You J, Cozzi P, Walsh B, Willcox M, Kearsley J, Russell P . Innovative biomarkers for prostate cancer early diagnosis and progression. Crit Rev Oncol Hematol. 2009; 73(1):10-22. DOI: 10.1016/j.critrevonc.2009.02.007. View

4.
McJimpsey E . Molecular Form Differences Between Prostate-Specific Antigen (PSA) Standards Create Quantitative Discordances in PSA ELISA Measurements. Sci Rep. 2016; 6:22050. PMC: 4766849. DOI: 10.1038/srep22050. View

5.
de la Rica R, Stevens M . Plasmonic ELISA for the ultrasensitive detection of disease biomarkers with the naked eye. Nat Nanotechnol. 2012; 7(12):821-4. DOI: 10.1038/nnano.2012.186. View